Cogent Biosciences Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis

Reuters

02/10

<a href="https://laohu8.com/S/COGT">Cogent Biosciences</a> Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis

Cogent Biosciences Inc. has announced multiple upcoming poster presentations featuring results from the SUMMIT trial evaluating bezuclastinib in adults with nonadvanced systemic mastocytosis (NonAdvSM) at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, scheduled for February 27–March 2, 2026, in Philadelphia, PA. The company recently submitted a New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration, based on positive clinical data from the pivotal SUMMIT trial. The presentations will cover expanded clinical results, exploratory analyses of bone formation markers, outcomes in patient subgroups with unmet needs, patient experiences, and correlations between symptom improvement and objective disease measures. The results will be presented at the conference and have not yet been publicly disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651659) on February 10, 2026, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2610362891"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610362891\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610362891?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610362891","market":"fut","top_or_hot":-1,"title":"Cogent Biosciences Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cogent Biosciences Inc. has announced multiple upcoming poster presentations featuring results from the SUMMIT trial evaluating bezuclastinib in adults with nonadvanced systemic mastocytosis (NonAdvSM) at the 2026 American Academy of Allergy Asthma &amp; Immunology (AAAAI) Annual Meeting, scheduled for February 27–March 2, 2026, in Philadelphia, PA. The company recently submitted a New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration, based on positive clinical data from the pivotal SUMMIT trial. The presentations will cover expanded clinical results, exploratory analyses of bone formation markers, outcomes in patient subgroups with unmet needs, patient experiences, and correlations between symptom improvement and objective disease measures. The results will be presented at the conference and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651659) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cogent Biosciences Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCogent Biosciences Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cogent Biosciences Inc. has announced multiple upcoming poster presentations featuring results from the SUMMIT trial evaluating bezuclastinib in adults with nonadvanced systemic mastocytosis (NonAdvSM) at the 2026 American Academy of Allergy Asthma &amp; Immunology (AAAAI) Annual Meeting, scheduled for February 27–March 2, 2026, in Philadelphia, PA. The company recently submitted a New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration, based on positive clinical data from the pivotal SUMMIT trial. The presentations will cover expanded clinical results, exploratory analyses of bone formation markers, outcomes in patient subgroups with unmet needs, patient experiences, and correlations between symptom improvement and objective disease measures. The results will be presented at the conference and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651659) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL2GJkSS:1","article_id":"2610362891","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610362891","pubTimestamp":1770728643,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cogent Biosciences Inc. has announced multiple upcoming poster presentations featuring results from the SUMMIT trial evaluating bezuclastinib in adults with nonadvanced systemic mastocytosis  at the 2026 American Academy of Allergy Asthma & Immunology  Annual Meeting, scheduled for February 27–March 2, 2026, in Philadelphia, PA. The company recently submitted a New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration, based on positive clinical data from the pivotal SUMMIT trial. The presentations will cover expanded clinical results, exploratory analyses of bone formation markers, outcomes in patient subgroups with unmet needs, patient experiences, and correlations between symptom improvement and objective disease measures. The results will be presented at the conference and have not yet been publicly disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","COGT":"Cogent Biosciences, Inc.","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","BK4505":"高瓴资本持仓","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Cogent Biosciences公布Bezuclastinib治疗非晚期系统性肥大细胞增多症的积极SUMMIT试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"COGT":0.9},"content_text":"Cogent Biosciences Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis\n    \n\n        Cogent Biosciences Inc. has announced multiple upcoming poster presentations featuring results from the SUMMIT trial evaluating bezuclastinib in adults with nonadvanced systemic mastocytosis (NonAdvSM) at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, scheduled for February 27–March 2, 2026, in Philadelphia, PA. The company recently submitted a New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration, based on positive clinical data from the pivotal SUMMIT trial. The presentations will cover expanded clinical results, exploratory analyses of bone formation markers, outcomes in patient subgroups with unmet needs, patient experiences, and correlations between symptom improvement and objective disease measures. The results will be presented at the conference and have not yet been publicly disclosed.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651659) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}